Modra’s oral formulation of docetaxel, ModraDoc006/r will bypass limitations associated with IV-delivered docetaxel and at the same time improve the bioavailability of the drug. ModraDoc006/r is currently in a Phase II study in patients with metastatic prostate cancer.
Docetaxel, a member of the taxane class of chemotherapeutics, is one of the most frequently applied anti-cancer drugs globally and is part of the standard treatment practices for several major cancer indications. Although part of docetaxel’s toxicity is related to its mode of action, a substantial level of toxicity is induced by the high initial docetaxel blood concentration after intravenous administration. Its excipients, polysorbate 80 and ethanol, are known to cause side effects. 


Modra Pharmaceuticals Announces Start of Phase II Study for its Lead Oral Chemotherapy in Patients with Metastatic Prostate Cancer
Read more

the IV to Oral switch

improving patient lives
Learn more


No current events
Read more